Posted On: 09/07/2014 11:39:10 PM
Post# of 30066
The LP002 study is also called the "bridge study." According to Gerald's blog back in early August, we were supposed to get the results of this "bridge study" first, and then a LymPro partner would be announced shortly thereafter.
Well, something else happened: we got a master service agreement with ICON even before the "bridge study" data was released. My sense is that this arrangement with ICON is in place of a "classic partnership" that we were all hoping for.
Translation: Gerald's negotiations with a Lympro JV partner fell through and he decided to go it alone with ICON! We can do this with ICON, but by not getting a big up front chunk of money from a Johnson & Johnson, Gerald is not going to have money to throw around making more acquisitions and funding Eltoprazine without dilution of some sort. (Using Lincoln Park Capital Money)
Things like this happen, but to then ask us to approve another billion authorized shares, when partnership deals haven't come together the way we'd all hoped....is pushing it....IMHO.
Well, something else happened: we got a master service agreement with ICON even before the "bridge study" data was released. My sense is that this arrangement with ICON is in place of a "classic partnership" that we were all hoping for.
Translation: Gerald's negotiations with a Lympro JV partner fell through and he decided to go it alone with ICON! We can do this with ICON, but by not getting a big up front chunk of money from a Johnson & Johnson, Gerald is not going to have money to throw around making more acquisitions and funding Eltoprazine without dilution of some sort. (Using Lincoln Park Capital Money)
Things like this happen, but to then ask us to approve another billion authorized shares, when partnership deals haven't come together the way we'd all hoped....is pushing it....IMHO.
(0)
(0)
